Quantumzyme Corp. (OTC: QTZM), a biotransformation company specializing in sustainable pharmaceutical manufacturing, announced that its team will attend the second annual BioLogic Summit, scheduled for January 19-22, 2026, in San Diego. The summit is a premier event focused on the application of machine learning and artificial intelligence for the design and optimization of biotherapeutics. Quantumzyme's participation underscores its strategic commitment to remaining engaged in the rapidly evolving fields of AI-enabled enzyme engineering and protein design.
According to the company, the conference offers an opportunity for its scientific leadership to participate in technical discussions, share insights with peers, and explore emerging advancements in disciplines that align with its internal development efforts and its proposed strategic evolution to Quantum Genesis AI Corp., pending FINRA approval. The BioLogic Summit is specifically designed for the growing community of hybrid scientists who integrate experimental and computational methods—a profile that reflects the expertise of the Quantumzyme team. By attending, the company aims to stay informed on the latest developments in generative AI, lab-in-the-loop optimization, and structure-based design approaches. These insights are intended to support the continued advancement of the company's platform and help ensure it remains aligned with the most relevant methodologies in the field.
“Innovation doesn’t happen in isolation. Being present and actively engaging with the brightest minds in our field is essential to driving our mission forward,” stated Naveen Kulkarni, CEO of Quantumzyme Corp. “The BioLogic Summit provides a valuable venue for our team to connect with individuals and organizations who are contributing to the future of AI in biologics. Our goal is to learn from the latest research, better understand emerging challenges, and explore potential collaborations that may support the adoption of greener and more efficient manufacturing approaches across the pharmaceutical industry.”
Quantumzyme Corp. focuses on advancing sustainable enzyme-based solutions for pharmaceutical manufacturing. By applying quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering, the company develops biocatalysts designed to enhance efficiency, reduce waste, and support environmentally responsible production. The company's integration of computational modeling with laboratory validation aims to deliver scalable, cost-effective biocatalysis solutions that improve industrial sustainability. For more information and updates, visit Quantumzyme's website and the company’s profile at OTC Markets.
